In the J.ast 20 years gammaglobullin products have been used more and more . in clinic ail. medi~ine for ) ' both the prevention and treaJtment of infectious diilseases. With the development of routine laboraJtory methods for tthe assessment of cell'ular and humoral immune competence, more pa:tients with · severe dmmunological deficiencies wiN be recognised, a.s will l!:hose with al[ shades of deficiency between complete absence of a fwctlilo:rral immune system and the normal state (Simons, 1971) . A major objective in the managemerilt of patients 1 with hypo-or agrunmaglobulilnaenria • arud other antibody defd:ciency (Sitates is Ito reduce their abnormality din susceptibility to infection. A survey carried out at the Hospiltal for Sick Chirrdren, London, revealed, that severe deflkiency of ceJilular amd humoral immunity was respcm:sible for · two per cent of ail.[ deaths (Berry, 1968) . CH:nical applica:tJiJon of the advances made in basic immunological research is not restricted merely to the recogniltion and dJ~agnosis of patients with immunolog1i·cal deficiency diseases, but also in raJtronal dimmu:nological thevapy. This paper discusses ·the enormous advances lin gammaglobulin therapy, its UJSes and limitations.
Replacement of immunoglobulins
One aspect of gammagUbbUJlin .therapy is lthe repl• acement of •l.he deficient end products iiJn those individuaLs in whom tlhere is impaired functlilon pf :immunogllobulin producing lymphoid tissues. ImmunoglobUtlin replacement will con1::io.lue untiill. means become avaiJ:ablie for overcom.in: g the centraJl celaul:ar defect. The second aspect is the liinhibitions of immune responses by :ilmmunoglobulin <thera-py.
The clinical appllkati'on of the gammaglobuliln <products for the prophylaxis aJild treatment of disease was reglil.ated accordiitng to empiric exper1ilence. Several authors with a large experience in gammagll~bulin therapy have come to the concliusion lthat a def.i.nJLte, c:r1ittical examination of the prophyilla.ctic and .therapeutic actions of gammag!l:obuJ!in preparations is not yet possiible (Baramdun, 1964) .
Ce:vtainly in 'll:Ormal, the use of gammagiJ.obulin.s to prevenlt viral !infections may be valuablle, but more interesting today are viral dnfections which ~annot be mam:aged by immunP.JZation procedures. In agammagilobulinaemic patients gammagllobul:Vn :i!S so far the most important prophylactre therapeutic agent to prevent repeated baoteruaill infections.
The dose necessary for !the prevention of several viraJJ. diseases i:s qulte low ' , it im.creases, however, as the incubation period advances. After onset of the disease and pa:vticulal'ly tin cases of serious or prolonged infectdon, high doses of gammaglobulin are necessary to support the body efficacioUSily in Clts resistance to the patlhogen. As a preventi;ve measure, gammaglobulim: i.s given rut regular intervals dn doses calcuJ.ated to provide tgG [evels of 200 mg per 100 ml i.e. levels suggested 13.8 bei.n.g neces. sary for protection (Soothill, 1962 One of the advallltages over the regull.ar intra:mu.scu.l·ar preparatlilon is .the dose to \ be g1iven. For example, 400 mg./Kg. of I.V.G.G. has been ~ven rim. a single infusion. This is equivalen 1 t to 2% ml./ Kg. of 16% i:ntramusculla. r gammaglobulin, or 50 ml. for a patient weighin1 g 20 Kg., an excessivel'y large voJume to be given intramusculli ar'ly to a child as part of routine management (Sinwns. , 1968).
There are differerut ways to treat · £Jtamdard · gamma.globuNn to obtain preparations free of :anlticompJement activi1ty. Table 1 compares the 7 prepara:tions of I.V.G.G.
The aciJd trealtment seems :to work we1 1' l initi:amy, although i1t has been noted that ~the reaCition may be incomplete (Schiff et all. , 1968 p1asmin digested material, and found that 55% of it was fragmented and rapidly catabo[yzed. In rt:he case of Gamma-Veru,n, the hydro~ysis with pepsiin and ~ow pH, iJt seems . apparently that 1the 1 duration of action of Gamma-Venin in the or-ganism Js relatively short, because the small fragments cannot be retained (Digge!llffiann et a1., 1964).
Furtlhermore, a part of the gammag[obu[ial. moleC!We (fragment Fe, III) is completely destroyed! by the trealtment mentlioned above. 'Dhis is just the part of the molecule which has no arrl!tibody actlilvilties, but is carrier of anUgenic pr01perties and of groups whkh bimd 1i 1n. · a non-specific way to complemen1t rund to various tiSSIUe ~tructures.
The treatment wli.lth pepsin and low ipH results in a gammaglobulin preparaJt~on without non-specific propertliletS but [i eaving intact the an· :ibody activities in qual!l!t~tative and quaE1tative terms. 'Dhe commercia lly I.V.G.G. made by Hyhmd Divrllsion Travenol Laboratories is resuspending !the fraction ill paste in normal sa.liJne and liS processed wang a polymeric fractionation agent. This is a preparation free of aggregates lllnd low 1iln. a.nJticompU.ementary activity. The in vivo haJllf lirfe was found to be comparabLe to inrtramuscu.Jlar preparrutions.
The gammag1lobmin products which have been available consist allmost exolUSiively of IgG and co:r1tain mere traces of IgA and IgM. The ev-aluation of the p:mmerOIUS ·wtibody assays show thrut antibodies against antiJgens are ~ocaJted mailnJy in tlhe IgG, ailltibodies against carbohydrate antigens are found iil1 IgM, and certain viral antibodies mainly in IgA. In the coiUJrse of the immund~a ltion process, IgM 1 antibodies a:ppea.r sooner than IgG, they have more ilntense aggil.utin,a:ting phage-neutralizing, comp[ement biooin.g, · and! hemolysing propertdles than IgG (Janeway et all., 1968). I!t is lmown that IgA 1s detected nort only iJn the serum, but also in the secretions of il:he mucous membranes rund m !the glands produd.Jng external secretions; it occurs in monomeric rund po~ymeryc form. The l~eveill of tJhe IgA fraotions in the secretions of the mucous membranes can be higher than that in the serum. Aill il:hese f;n, dings promoted the manufacture of IgA and IgM preparations fo, r clinical applications.
Results oblbained by Hobbs (1968) and ather inve.stdlgators (Stiehm and FuJd.enberg, 1966) have al1so proved
. ' The ratilonale for this procedure is based on experimental finding that t:he passive •admini~s.traltion of antii.lbody to run anima1 l previous.ly ch a.lenged wlth an tl:igen can suppress the production ·of endogenous antibody (UHR and Muliller, 1968) . This principJ!e has recenitly been applied tin the prevention of Rh haemolytrc disease. The im.tramuscuaar injectliiO'lll of a very small volume of high titre :anti-Rh (D) antibody i1 s suf:Dicient to suppress the productoon of red cell damaging amrtibody. The mechanism of thLs !phenomenon ha.s not been elucidated.
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The formation' of a1 ntil gen-anJtli• bod'y comp~exes are being incriminated in the pathogenesliiS of ' an increasing number of disease states. These inc!Jude disea.se.s as apparently unrelated as acUJte GlomeruJomephritis, serum s.ickn.e;ss, systemic LUipus Erythematosus, •and ren·al aJUograft re}ec-:won. Wirtih the progres, sive :use of immunoglobulin and antibody solutions the number of these disorders may even increase. Another area where suppression of immunoglobu-' lin production , bY' specific antiserum may find an appaication is 11n the control of IgE d'epend1 en1 t reactions that are unresponsilve to convemtional thera1py. R eaginic antibodies of the IgE o11a.s: s have been shown to be jnvolved in anergic dii sordlers inc1u-dl'!ng hay fever, as/thma and eczema (Ishizaka et all., 1966) . It is conceivable that the imfusion of anti IgE anti.sera may be of tlherapeutlnc benefilt in intraetable cas, e, s: .
In 1 the preparation of diillmune antisera whiilch cannot be ohtaim,ed from human sera and so have to be raised in experimental am.~mals., a major problem i1s to raise a111 Uhodoes to a restricted range of antigenic determin31llts. In tlhe prodJuct[oo of anti,_ l)rmphocyte serum (ALS) for example, it ils wellli recognised tlhat the injection of humam1 [ymphocyltes from a1 ny of several sources results in the appearance not on~y of antilymphocyte antli:bocHes but also of anltibodies d'irected agailnSit red cells, platelets and other cellJI types. El' iminaltion of these 3Jll!t~bodies from the f1ilna~ preparation is a major practiicall problem. Absonption )Procedures are time consumt:Jng and pose the dliffiiculty O· f obtail ning red cellls and other cells in numbers sufficient for complete absorption of 1the crude ALS (Simons, 1971) . InMbition of haemagglutinins a:nd , otiher undes.ired antibodies by the passive admilnisJtration of ant tilsera at the 1time of lymphocyte immuni,srution woilrld be a much more satisfactory a1 lternative.
LimiJtati!ons
The idea1l prepara1 Uon for ,gammaglobulin thera!py wou[d be a gammagl:obu[in wiJthout severe alteration of the molecules, but only slighit rearrangements of the intramo, lecular gtructure. It coullld be ilnjecited' mtravenous1ly without risk and wocufid be retained in the organism bec· ause of in1 t:ac1t molecular size :a.nd intact t11s-sue-hinding capacity.
St:Jmons et ·al., (1968) reported that even though · the anlticomplementary activity of the I.V.G.G. has been raduced by acid pepsi1n treatment, a number of ;wntoward reactions: to anfusion of this: ma:terit aJ were observed. 'llhese inc[l uded pallor, t'Cstlessness, t:achycardia, drowsiness, headache, nrausea a:nd abdominal discomforlt. lt was found that the occurrance ;and . severity of tihese. side effects were ·dlependent on the rate of iJnfusion, as they :appeared whenever 1:1he ralte exceeded ' a certaiiU critical value. They were of the opinion thart these ,reactiollls ;might he partly due I to temporary occ1usi i'on of small blood ve.s.se1!s. by agg1Lutinratedi ceJIJ.s, in , accor r'dance wirt:ih their findings tha;t I.V.G.G. agglliutinated erythrocytes and leucocytes an vitro. All these findings of limittations indicate · that dlnical[.y modified gammaglobullin preparations sihow various degrees of aggrr egation, , reaggregation and fragmenltation which make 1 them !less tJhan desdtrahle for cl~ndcal use.
Complllete removal of <the Fe fragment and iit.s associated an~ticom plemenltary activity can , be accompliished only at the expense of splitting off tihis fragme:111t, wilth the conseque:nJt diminution in tis, sue biiiilding affintty, and reduction of molecular size. Thi.s in turn is accompanJied by increaslilngly >rapid , elimination in, the urine with a reduction of the i:n vivo ha1lf-life to a leve1 f.mpracticahle for li ong term !therapy. In Simons' serial prutient. s using Gamma-Venin, 80% of the infused I 125 labeled ' ma1 teriail were recovered i'lll the urilne during the first 24 hours: . SUMARMO Anolther limita!l:lilon of I.V.G.G. is its use for 1 the rout,ine managemenlt of chilldren with immunogllobuliin deficlilency • staies which is restriclted by the ~ge of the chHd, since small infan1 ts -are ru1likely to co-o1perate wiith monthly io:11travenous iin!Lusions. It may alll s10 be i1napplicable •to those children' who ,require umusually [arge maintenance doses or who have low threshold for s8de effects, because the pmlonged duration of infusion :rrequi1 red would 'then preCilude the pra cticability of r eguiar thempy on an oUJtipa!ti ilent , basis. ;
I.V.G.G. 1s : probably less suited than fresh prrlasma 'to the emergency treatment of lli[e threatenr ing infect.i on in patren!ts known to be a gammagrlobuHnaemic or in whom with a strong suspicion of defident antibody formatl~on, since it contains negiigible amounJts of IgA and IgM. Thus i1 n the emergency therapy of agammaglohul:inlaemic chilldren who have deficiency of all 3 major dlmmUinoglobuJim classes, it may be preferable to :administer fresh pllasma ( Stiehm gammaglohulin may yet result in a IJowe'I' anticomp~emenltary activlilty, a convenienltl ly long biologie:a~ half-J:ife, mriched wi!th IgA and IgM, and · a reasonable price. Summary An enormollls progress inr gammaglobulin pre~paration, · which can be adminJilstra.ted intravenouSily ha, s been described. .
;
Gamma.globulin · therapy is now ind!ica!ted ]n: 1. The prevenrttio' n and treatment of infectious diseases dtn hypo (aga.mmagJlobu[~nemic patients. 2. IgM enriched rilmmunog~lobuiliin.s are given to ile:s; s than 1500 gram underwei, gh!t newborns to prevemt infection by Gram negalbive !pathogens. 3. Hy· perimmruneglobuU,iln is us. ed for the treatment of numerous infectious dli.se.ases. . 4. Studies in the ' use of antibody agruiiruslt hepatiti.s-B antigen in the prophy[,axiJS of hepatitis B are in progress. . 5. Anlti-rhesus serum app~iled shortly after delivery can prevent morbus hemolyJticus neonatorum in for<thcomilng .siblings.
However, limitat1i10ns to the wide spread use of immuno.giobulins still exisl t.
